MYNZ logo

Mainz Biomed BV (MYNZ) Company Overview

Profile

Full Name:

Mainz Biomed N.V.

Sector:

Healthcare

Country:

Germany

IPO:

November 5, 2021

Indexes:

Not included

Description:

MYNZ (Mainz Biomed BV) is a biotechnology company focused on developing innovative diagnostic solutions for early disease detection. They specialize in molecular tests, particularly for gastrointestinal diseases, aiming to improve patient outcomes through advanced technology and personalized healthcare solutions.

Key Details

Price

$7.21

Annual Revenue

$895.50 K(+68.99% YoY)

Annual EPS

-$64.80(+12.90% YoY)

Annual ROE

-303.20%

Beta

0.22

Events Calendar

Earnings

Next earnings date:

Feb 7, 2025

Recent quarterly earnings:

Oct 21, 2024

Recent annual earnings:

Apr 10, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 3, 2024

Analyst ratings

Recent major analysts updates

Nov 25, 24 HC Wainwright & Co.
Neutral
Apr 12, 24 Cantor Fitzgerald
Neutral
Mar 6, 24 HC Wainwright & Co.
Buy
Nov 21, 23 Cantor Fitzgerald
Neutral
Nov 20, 23 HC Wainwright & Co.
Buy
Sep 26, 23 Cantor Fitzgerald
Overweight
Sep 22, 23 HC Wainwright & Co.
Buy
Sep 14, 23 Cantor Fitzgerald
Overweight
Aug 22, 23 Cantor Fitzgerald
Overweight
Aug 18, 23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
MYNZ
globenewswire.comJanuary 21, 2025

eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the second half and reporting in the Fourth Quarter of 2025 BERKELEY, Calif. and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of eAArly DETECT 2, a U.S. feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over a population of approximately 2,000 patients, all of average risk, to validate the industry leading results of previous feasibility studies, which included average risk and identified risk patients.

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
MYNZ
globenewswire.comDecember 19, 2024

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
MYNZ
globenewswire.comDecember 16, 2024

BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
MYNZ
benzinga.comDecember 3, 2024

Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.

Mainz Biomed Announces Stock Split
Mainz Biomed Announces Stock Split
Mainz Biomed Announces Stock Split
MYNZ
globenewswire.comNovember 29, 2024

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
MYNZ
globenewswire.comOctober 21, 2024

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
MYNZ
globenewswire.comOctober 1, 2024

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
MYNZ
globenewswire.comSeptember 18, 2024

BERKELEY, Calif. and MAINZ, Germany, Sept.

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
MYNZ
globenewswire.comJuly 25, 2024

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Provides Half Year 2024 Corporate Update
Mainz Biomed Provides Half Year 2024 Corporate Update
Mainz Biomed Provides Half Year 2024 Corporate Update
MYNZ
globenewswire.comJuly 2, 2024

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Mainz Biomed BV?
  • Does Mainz Biomed BV pay dividends?
  • What sector is Mainz Biomed BV in?
  • What industry is Mainz Biomed BV in?
  • What country is Mainz Biomed BV based in?
  • When did Mainz Biomed BV go public?
  • Is Mainz Biomed BV in the S&P 500?
  • Is Mainz Biomed BV in the NASDAQ 100?
  • Is Mainz Biomed BV in the Dow Jones?
  • When was Mainz Biomed BV's last earnings report?
  • When does Mainz Biomed BV report earnings?
  • Should I buy Mainz Biomed BV stock now?

What is the ticker symbol for Mainz Biomed BV?

The ticker symbol for Mainz Biomed BV is NASDAQ:MYNZ

Does Mainz Biomed BV pay dividends?

No, Mainz Biomed BV does not pay dividends

What sector is Mainz Biomed BV in?

Mainz Biomed BV is in the Healthcare sector

What industry is Mainz Biomed BV in?

Mainz Biomed BV is in the Diagnostics & Research industry

What country is Mainz Biomed BV based in?

Mainz Biomed BV is headquartered in Germany

When did Mainz Biomed BV go public?

Mainz Biomed BV's initial public offering (IPO) was on November 5, 2021

Is Mainz Biomed BV in the S&P 500?

No, Mainz Biomed BV is not included in the S&P 500 index

Is Mainz Biomed BV in the NASDAQ 100?

No, Mainz Biomed BV is not included in the NASDAQ 100 index

Is Mainz Biomed BV in the Dow Jones?

No, Mainz Biomed BV is not included in the Dow Jones index

When was Mainz Biomed BV's last earnings report?

Mainz Biomed BV's most recent earnings report was on Oct 21, 2024

When does Mainz Biomed BV report earnings?

The next expected earnings date for Mainz Biomed BV is Feb 7, 2025

Should I buy Mainz Biomed BV stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions